search
Back to results

Intravenous Human Albumin In Improving Pancreaticoduodenectomy Outcomes

Primary Purpose

Pancreaticoduodenectomy, Pancreatic Fistula, Delayed Gastric Emptying

Status
Recruiting
Phase
Phase 2
Locations
Malaysia
Study Type
Interventional
Intervention
Human albumin
Sponsored by
Universiti Kebangsaan Malaysia Medical Centre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pancreaticoduodenectomy focused on measuring Pancreaticoduodenectomy, Postoperative Pancreatic Fistula, Pancreatic Cancer, Intravenous Human Albumin

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • All patients undergoing pancreaticoduodenectomy that can consent to the study

Exclusion Criteria:

  • Patients with known allergy to human albumin
  • Patients of American Society of Anaesthesiologist (ASA) physical status class 3 and above.

Sites / Locations

  • Universiti Kebangsaan Malaysia Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control Arm

Treatment Arm

Arm Description

Standard intraoperative fluid regime

Intravenous human albumin 1g/kg at skin incision running at 100ml/hour

Outcomes

Primary Outcome Measures

Overall Complications
Complications are defined as any deviation from the normal postoperative course, graded from I to V following the Clavien-Dindo classification of complications whereby Grade I are mild complications not needing any additional interventions and Grade V equates to the most severe complication which is death.

Secondary Outcome Measures

Length of Hospital Stay
Duration of days of hospitalization
Length of ICU stay
Duration of stay in ICU (in days), where relevant
Postoperative Pancreatic Fistula (POPF) rates
Rates of postoperative pancreatic fistula
Delayed Gastric Emptying
Rates of prolonged gastroparesis
Ease of surgery
Measured in duration of surgery (in hours & mins)

Full Information

First Posted
March 25, 2020
Last Updated
June 15, 2022
Sponsor
Universiti Kebangsaan Malaysia Medical Centre
search

1. Study Identification

Unique Protocol Identification Number
NCT04418739
Brief Title
Intravenous Human Albumin In Improving Pancreaticoduodenectomy Outcomes
Official Title
Intravenous Human Albumin In Improving Pancreaticoduodenectomy Outcomes
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 27, 2020 (Actual)
Primary Completion Date
November 26, 2022 (Anticipated)
Study Completion Date
November 26, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universiti Kebangsaan Malaysia Medical Centre

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Pancreaticoduodenectomy (PD), more commonly known as Whipple's surgery is the mainstay treatment for pancreatic head and periampullary cancer. Factors contributing to PD outcomes are broadly categorized to disease-related, patient-related and operative factors. Whereas an inexhaustible list of study exists on looking at reducing PD complication rates with respect to the above-mentioned factors, it was only recently that more attention has been given to the impact of perioperative and intraoperative fluid regimes on PD outcomes. This study takes interest in the impact of intraoperative fluid regimes on PD outcomes. The objective of this investigation is to compare the outcomes with the use of intraoperative intravenous human albumin versus standard intraoperative fluid regimes.
Detailed Description
This is a randomized controlled trial being conducted at the Universiti Kebangsaan Malaysia Medical Center (UKMMC) with two arms; the control and treatment arms. The treatment arm will receive intravenous human albumin intraoperatively whilst the control arm will receive standard intraoperative fluid regimes. Primary endpoint will be overall complication rates whilst secondary endpoints are length of hospitalization, length of ICU care, duration of gastroparesis, pancreatic fistula rates, surgical site infection rates, duration of surgery and intraoperative bleeding. Beyond the intraoperative fluid regimes, postoperative care follows the standardised UKMMC Enhanced Recovery After Surgery (ERAS) protocols which saw an improvement in overall outcomes in patients who underwent pancreaticoduodenectomies (PD). Preoperative care will include nutrition optimisation, counselling, antimicrobial prophylaxis, perioperative glycemic control and near-zero fluid balance. Data collection will include: i. preoperative data: age, sex, ethnicity, BMI on admission, date of admission, comorbidities and the New York Heart Association (NYHA) functional status classification. Further information will include biochemical markers such as serum albumin albumin, white cell count (WCC), renal functions. ii. Intraoperative information: duration of surgery, estimated blood loss, pancreatic duct size, pancreatic texture, amount and type of fluid administered, fluid balances and type of anastomoses. iii. postoperative data: fluid balances and renal function of postoperative day 1 to 3, duration of ICU stay, readmission to ICU, length of hospital stay, duration to standard feeds, grading of pancreatic fistula (where relevant), surgical site infection, duration to removal of urinary catheter, cardiac complications, renal and pulmonary complications, deep vein thrombosis, re-operation, and mortality.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreaticoduodenectomy, Pancreatic Fistula, Delayed Gastric Emptying, Pancreatic Cancer, Anastomotic Leak
Keywords
Pancreaticoduodenectomy, Postoperative Pancreatic Fistula, Pancreatic Cancer, Intravenous Human Albumin

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
This is a randomized controlled trial conducted at the University Kebangsaan Malaysia Medical Center (UKMMC) with two arms; a control a treatment arm. The treatment arm will receive intravenous human albumin intraoperatively whilst the control arm will receive standard intraoperative fluid regimes.
Masking
Participant
Allocation
Randomized
Enrollment
122 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control Arm
Arm Type
No Intervention
Arm Description
Standard intraoperative fluid regime
Arm Title
Treatment Arm
Arm Type
Experimental
Arm Description
Intravenous human albumin 1g/kg at skin incision running at 100ml/hour
Intervention Type
Drug
Intervention Name(s)
Human albumin
Intervention Description
Intravenous human albumin given at a maximum dose of 1g/kg at skin incision which is infused at 100ml/hour
Primary Outcome Measure Information:
Title
Overall Complications
Description
Complications are defined as any deviation from the normal postoperative course, graded from I to V following the Clavien-Dindo classification of complications whereby Grade I are mild complications not needing any additional interventions and Grade V equates to the most severe complication which is death.
Time Frame
Postoperative complications are recorded from date of surgery to date of documented complications including death, assessed from date of surgery to date of discharge or death, whichever came earlier, for up to 12 months.
Secondary Outcome Measure Information:
Title
Length of Hospital Stay
Description
Duration of days of hospitalization
Time Frame
From date of surgery to date of discharge or date of death, whichever came earlier, assessed up to 12 months
Title
Length of ICU stay
Description
Duration of stay in ICU (in days), where relevant
Time Frame
From date of surgery to date of discharge or date of death, whichever came earlier, assessed up to 12 months
Title
Postoperative Pancreatic Fistula (POPF) rates
Description
Rates of postoperative pancreatic fistula
Time Frame
From date of surgery to date of discharge or date of death, whichever came earlier, assessed up to 12 months
Title
Delayed Gastric Emptying
Description
Rates of prolonged gastroparesis
Time Frame
From date of surgery to date of discharge or date of death, whichever came earlier, assessed up to 12 months
Title
Ease of surgery
Description
Measured in duration of surgery (in hours & mins)
Time Frame
Duration is measured from the start time till the end time of surgery and will be assessed at the end of surgery for up to 12 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All patients undergoing pancreaticoduodenectomy that can consent to the study Exclusion Criteria: Patients with known allergy to human albumin Patients of American Society of Anaesthesiologist (ASA) physical status class 3 and above.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ian Chik
Phone
+60123243404
Email
ianchikmd@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Sarah I Liew
Phone
+601112218229
Email
liew4689@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ian Chik
Organizational Affiliation
Universiti Kebangsaan Malaysia Medical Center
Official's Role
Study Chair
Facility Information:
Facility Name
Universiti Kebangsaan Malaysia Medical Center
City
Kuala Lumpur
ZIP/Postal Code
56000
Country
Malaysia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ian Chik
Phone
+60123243404
Email
ianchikmd@gmail.com
First Name & Middle Initial & Last Name & Degree
Sarah I Liew, MBBS
Phone
+601112218229
Email
liew4689@gmail.com
First Name & Middle Initial & Last Name & Degree
Ian Chik
First Name & Middle Initial & Last Name & Degree
Farrah-Hani Imran
First Name & Middle Initial & Last Name & Degree
Azarinah Izaham
First Name & Middle Initial & Last Name & Degree
Zamri Zuhdi
First Name & Middle Initial & Last Name & Degree
Azlanuddin Azman
First Name & Middle Initial & Last Name & Degree
Razman Jarmin
First Name & Middle Initial & Last Name & Degree
Sarah I Liew
First Name & Middle Initial & Last Name & Degree
Fahrol F Jaafar

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
14578723
Citation
Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, Rasmussen MS, Lanng C, Wallin L, Iversen LH, Gramkow CS, Okholm M, Blemmer T, Svendsen PE, Rottensten HH, Thage B, Riis J, Jeppesen IS, Teilum D, Christensen AM, Graungaard B, Pott F; Danish Study Group on Perioperative Fluid Therapy. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg. 2003 Nov;238(5):641-8. doi: 10.1097/01.sla.0000094387.50865.23.
Results Reference
result
PubMed Identifier
15273542
Citation
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae.
Results Reference
result
PubMed Identifier
23079762
Citation
Lassen K, Coolsen MM, Slim K, Carli F, de Aguilar-Nascimento JE, Schafer M, Parks RW, Fearon KC, Lobo DN, Demartines N, Braga M, Ljungqvist O, Dejong CH; ERAS(R) Society; European Society for Clinical Nutrition and Metabolism; International Association for Surgical Metabolism and Nutrition. Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS(R)) Society recommendations. Clin Nutr. 2012 Dec;31(6):817-30. doi: 10.1016/j.clnu.2012.08.011. Epub 2012 Sep 26.
Results Reference
result
PubMed Identifier
25115420
Citation
Lavu H, Sell NM, Carter TI, Winter JM, Maguire DP, Gratch DM, Berman RA, Feil MG, Grunwald Z, Leiby BE, Pequignot EC, Rosato EL, Yeo CJ. The HYSLAR trial: a prospective randomized controlled trial of the use of a restrictive fluid regimen with 3% hypertonic saline versus lactated Ringers in patients undergoing pancreaticoduodenectomy. Ann Surg. 2014 Sep;260(3):445-53; discussion 453-5. doi: 10.1097/SLA.0000000000000872.
Results Reference
result
PubMed Identifier
20100698
Citation
Boldt J. Use of albumin: an update. Br J Anaesth. 2010 Mar;104(3):276-84. doi: 10.1093/bja/aep393. Epub 2010 Jan 24.
Results Reference
result
PubMed Identifier
65572
Citation
Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977 Feb 26;1(8009):466-9. doi: 10.1016/s0140-6736(77)91953-5.
Results Reference
result
Citation
Ling, Q. Y., Ariffin, A. C., Azman, A., Zuhdi, Z., Othman, H., & Jarmin, R. (2017). Early postoperative outcomes for pancreaticoduodenectomy before and after implementation of enhanced recovery after surgery (ERAS) protocol. Surgical Chronicles, 22(3), 109-113
Results Reference
result
PubMed Identifier
18358585
Citation
Soar J, Pumphrey R, Cant A, Clarke S, Corbett A, Dawson P, Ewan P, Foex B, Gabbott D, Griffiths M, Hall J, Harper N, Jewkes F, Maconochie I, Mitchell S, Nasser S, Nolan J, Rylance G, Sheikh A, Unsworth DJ, Warrell D; Working Group of the Resuscitation Council (UK). Emergency treatment of anaphylactic reactions--guidelines for healthcare providers. Resuscitation. 2008 May;77(2):157-69. doi: 10.1016/j.resuscitation.2008.02.001. Epub 2008 Mar 20.
Results Reference
result
PubMed Identifier
28040257
Citation
Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink MG, Conlon K, Del Chiaro M, Falconi M, Fernandez-Cruz L, Fernandez-Del Castillo C, Fingerhut A, Friess H, Gouma DJ, Hackert T, Izbicki J, Lillemoe KD, Neoptolemos JP, Olah A, Schulick R, Shrikhande SV, Takada T, Takaori K, Traverso W, Vollmer CR, Wolfgang CL, Yeo CJ, Salvia R, Buchler M; International Study Group on Pancreatic Surgery (ISGPS). The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017 Mar;161(3):584-591. doi: 10.1016/j.surg.2016.11.014. Epub 2016 Dec 28.
Results Reference
result
PubMed Identifier
17981197
Citation
Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Traverso LW, Yeo CJ, Buchler MW. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007 Nov;142(5):761-8. doi: 10.1016/j.surg.2007.05.005.
Results Reference
result
PubMed Identifier
7992937
Citation
Laxenaire MC, Charpentier C, Feldman L. [Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study]. Ann Fr Anesth Reanim. 1994;13(3):301-10. doi: 10.1016/s0750-7658(94)80038-3. French.
Results Reference
result
PubMed Identifier
21107104
Citation
Fischer M, Matsuo K, Gonen M, Grant F, Dematteo RP, D'Angelica MI, Mascarenhas J, Brennan MF, Allen PJ, Blumgart LH, Jarnagin WR. Relationship between intraoperative fluid administration and perioperative outcome after pancreaticoduodenectomy: results of a prospective randomized trial of acute normovolemic hemodilution compared with standard intraoperative management. Ann Surg. 2010 Dec;252(6):952-8. doi: 10.1097/SLA.0b013e3181ff36b1.
Results Reference
result

Learn more about this trial

Intravenous Human Albumin In Improving Pancreaticoduodenectomy Outcomes

We'll reach out to this number within 24 hrs